Abstract
Despite major advances in the molecular definition of the disease, screening and therapy, non-small cell lung cancer (NSCLC) is still characterized by a disappointing overall survival, depending on subtype and tumor stage. To address this challenge, in the last years the therapeutic algorithm of NSCLC has become much more complex and articulated, with different kinds of drugs, including chemotherapy, targeted-based agents, angiogenesis inhibitors and immunotherapy, and multiple lines of treatments, for patients with squamous and non-squamous hystology, EGFR mutation and ALK rearrangement. This short viewpoint describes the emerging strategies for the management of NSCLC, indicating how a personalized approach, characterized by a specific multidisciplinary involvement, implies a process that starts with early detection and includes surgery and systemic therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 173-179 |
| Number of pages | 7 |
| Journal | International Journal of Biochemistry and Cell Biology |
| Volume | 78 |
| DOIs | |
| Publication status | Published - Sep 1 2016 |
Fingerprint
Keywords
- ALK
- Early detection
- EGFR
- Immunotherapy
- Non-small cell lung cancer (NSCLC)
- Personalized medicine
- Stereotactic ablative radiotherapy (SABR)
- Video-assisted thoracoscopic surgery (VATS)
ASJC Scopus subject areas
- Biochemistry
- Cell Biology
Cite this
Management of non-small cell lung cancer in the era of personalized medicine. / Rocco, Gaetano; Morabito, Alessandro; Leone, Alessandra; Muto, Paolo; Fiore, Francesco; Budillon, Alfredo.
In: International Journal of Biochemistry and Cell Biology, Vol. 78, 01.09.2016, p. 173-179.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Management of non-small cell lung cancer in the era of personalized medicine
AU - Rocco, Gaetano
AU - Morabito, Alessandro
AU - Leone, Alessandra
AU - Muto, Paolo
AU - Fiore, Francesco
AU - Budillon, Alfredo
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Despite major advances in the molecular definition of the disease, screening and therapy, non-small cell lung cancer (NSCLC) is still characterized by a disappointing overall survival, depending on subtype and tumor stage. To address this challenge, in the last years the therapeutic algorithm of NSCLC has become much more complex and articulated, with different kinds of drugs, including chemotherapy, targeted-based agents, angiogenesis inhibitors and immunotherapy, and multiple lines of treatments, for patients with squamous and non-squamous hystology, EGFR mutation and ALK rearrangement. This short viewpoint describes the emerging strategies for the management of NSCLC, indicating how a personalized approach, characterized by a specific multidisciplinary involvement, implies a process that starts with early detection and includes surgery and systemic therapy.
AB - Despite major advances in the molecular definition of the disease, screening and therapy, non-small cell lung cancer (NSCLC) is still characterized by a disappointing overall survival, depending on subtype and tumor stage. To address this challenge, in the last years the therapeutic algorithm of NSCLC has become much more complex and articulated, with different kinds of drugs, including chemotherapy, targeted-based agents, angiogenesis inhibitors and immunotherapy, and multiple lines of treatments, for patients with squamous and non-squamous hystology, EGFR mutation and ALK rearrangement. This short viewpoint describes the emerging strategies for the management of NSCLC, indicating how a personalized approach, characterized by a specific multidisciplinary involvement, implies a process that starts with early detection and includes surgery and systemic therapy.
KW - ALK
KW - Early detection
KW - EGFR
KW - Immunotherapy
KW - Non-small cell lung cancer (NSCLC)
KW - Personalized medicine
KW - Stereotactic ablative radiotherapy (SABR)
KW - Video-assisted thoracoscopic surgery (VATS)
UR - http://www.scopus.com/inward/record.url?scp=84981719332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981719332&partnerID=8YFLogxK
U2 - 10.1016/j.biocel.2016.07.011
DO - 10.1016/j.biocel.2016.07.011
M3 - Review article
AN - SCOPUS:84981719332
VL - 78
SP - 173
EP - 179
JO - International Journal of Biochemistry and Cell Biology
JF - International Journal of Biochemistry and Cell Biology
SN - 1357-2725
ER -